The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Table 6 Incremental cost-utility ratios of ranibizumab referent to laser photocoagulation, intravitreal pegaptanib, and PDT

Intervention	QALY gain	Cost	Avr. $/QALY	Incr. $/QALY^a
Ranibizumab, 2015	1.372	$24,082	$17,552	NA
Laser	0.25717	$1071	$6157	$20,643
Pegaptanib, intravitreal	0.83417	$22,175	$26,589	$3546
PDT	0.74715	$14,057	$18,818	$16,044

All cost-utility analyses in this table use patient utilities, a 3rd party insurer cost perspective and 2nd-eye model. PDT photodynamic therapy with verteporfin, QALY dollars expended per quality-adjusted life year gained, or cost-utility ratio, Avr. $/QALY average cost-utility ratio, Incr. NA not applicable, ranib. ranibizumab therapy. All outcomes and costs are discounted at 3% annually
^aIncremental cost-utility ratio of ranibizumab referent to the other interventions

ISSN: 2056-9920